Investing.com - Regeneron Pharma (NASDAQ:REGN) reported on Friday fourth quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Regeneron Pharma announced earnings per share of $23.72 on revenue of $4.95B. Analysts polled by Investing.com anticipated EPS of $20.06 on revenue of $4.5B.
Regeneron Pharma shares are down 1.71% from the beginning of the year, still down 9.60% from its 52 week high of $686.62 set on September 3, 2021. They are outperforming the S&P 500 which is down 6.06% from the start of the year.
Regeneron Pharma follows other major Healthcare sector earnings this month
Regeneron Pharma's report follows an earnings beat by UnitedHealth on January 19, who reported EPS of $4.48 on revenue of $73.74B, compared to forecasts EPS of $4.3 on revenue of $72.98B.
J&J had beat expectations on January 25 with fourth quarter EPS of $2.13 on revenue of $24.8B, compared to forecast for EPS of $2.12 on revenue of $25.28B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar